In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach

Executive Summary

Absent proof of an overall survival benefit, new data suggesting a link between longer-term use of Celgene Corp.’s blockbuster Revlimid and secondary malignancies in multiple myeloma may encourage a cautious approach to maintenance treatment, threatening a major expansion for the drug.
Advertisement

Related Content

Celgene Secures Revlimid Frontline Myeloma Approval
Counting The Cost Of Delay For Revlimid Front-line Myeloma Approval
Secondary Cancers Resurface In Updated Revlimid Maintenance Trial Data
Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype

Topics

Advertisement
UsernamePublicRestriction

Register

PS052943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel